Functional MRI and CT biomarkers in oncology

被引:21
|
作者
Winfield, J. M. [1 ,2 ,3 ,4 ]
Payne, G. S. [1 ,2 ]
deSouza, N. M. [1 ,2 ]
机构
[1] Inst Canc Res, CRUK Imaging Ctr, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Inst Canc Res, MRI Unit, Sutton SM2 5PT, Surrey, England
[4] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England
基金
英国医学研究理事会;
关键词
MRI; CT; Biomarker; Oncology; APPARENT DIFFUSION-COEFFICIENT; MAGNETIC-RESONANCE-SPECTROSCOPY; CELL LUNG-CANCER; CONTRAST-ENHANCED MRI; IN-VIVO; PROSTATE-CANCER; BREAST-CANCER; VESSEL SIZE; DCE-MRI; IMAGING BIOMARKERS;
D O I
10.1007/s00259-014-2979-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Imaging biomarkers derived from MRI or CT describe functional properties of tumours and normal tissues. They are finding increasing numbers of applications in diagnosis, monitoring of response to treatment and assessment of progression or recurrence. Imaging biomarkers also provide scope for assessment of heterogeneity within and between lesions. A wide variety of functional parameters have been investigated for use as biomarkers in oncology. Some imaging techniques are used routinely in clinical applications while others are currently restricted to clinical trials or preclinical studies. Apparent diffusion coefficient, magnetization transfer ratio and native T-1 relaxation time provide information about structure and organization of tissues. Vascular properties may be described using parameters derived from dynamic contrast-enhanced MRI, dynamic contrast-enhanced CT, transverse relaxation rate (R-2*), vessel size index and relative blood volume, while magnetic resonance spectroscopy may be used to probe the metabolic profile of tumours. This review describes the mechanisms of contrast underpinning each technique and the technical requirements for robust and reproducible imaging. The current status of each biomarker is described in terms of its validation, qualification and clinical applications, followed by a discussion of the current limitations and future perspectives.
引用
收藏
页码:562 / 578
页数:17
相关论文
共 50 条
  • [31] Utilization of functional MRI in the diagnosis and management of cervical cancer
    Matani, Hirsch
    Patel, Ankur K. K.
    Horne, Zachary D. D.
    Beriwal, Sushil
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Biomarkers in oncology drug development
    Hodgson, Darren R.
    Whittaker, Robin D.
    Herath, Athula
    Amakye, Dereck
    Clack, Glen
    MOLECULAR ONCOLOGY, 2009, 3 (01) : 24 - 32
  • [33] Biologically conformal treatment: biomarkers and functional imaging in radiation oncology
    Lawrence, Yaccov Richard
    Werner-Wasik, Maria
    Dickert, Adam P.
    FUTURE ONCOLOGY, 2008, 4 (05) : 689 - 704
  • [34] DCE-MRI: a review and applications in veterinary oncology
    Boss, M. Keara
    Muradyan, N.
    Thrall, D. E.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2013, 11 (02) : 87 - 100
  • [35] Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing
    Ong, Frank S.
    Das, Kingshuk
    Wang, Jay
    Vakil, Hana
    Kuo, Jane Z.
    Blackwell, Wendell-Lamar B.
    Lim, Stephen W.
    Goodarzi, Mark O.
    Bernstein, Kenneth E.
    Rotter, Jerome I.
    Grody, Wayne W.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2012, 12 (06) : 593 - 602
  • [36] CT or MRI
    Tez, Mesut
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (02) : E25 - E25
  • [38] Biomarkers of fatigue in oncology: A systematic review
    Vanrusselt, Deveny
    Sleurs, Charlotte
    Arif, Mahnoor
    Lemiere, Jurgen
    Verschueren, Sabine
    Uyttebroeck, Anne
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 194
  • [39] MRI Radiogenomics in Precision Oncology: New Diagnosis and Treatment Method
    Yin, Xiao-Xia
    Gao, Mingyong
    Wang, Wei
    Zhang, Yanchun
    COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE, 2022, 2022
  • [40] An introduction to functional and molecular imaging with MRI
    Gallagher, F. A.
    CLINICAL RADIOLOGY, 2010, 65 (07) : 557 - 566